Search

A new tool called optogenetics is revealing clues about the function of a promising experimental therapy derived from stem cells.

Metastatic cancer is responsible for 90 percent of cancer deaths. The promise of nanomedicines for the treatment of disseminated tumors is the ability to target therapies directly to disease sites, avoiding toxic side effects by preventing accumulation in healthy tissues. We are developing new nanoparticle drug delivery systems to specifically target metastatic tumors. We collaborate with cancer biologists and clinicians to translate these therapies to the bedside.